# Source check — claim d85a6f7fa5fa13068d99306da8711eb1f3a8d478903769605a431e1ba532b85a

Claim: Abstract extract PMID 40896880 ("Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial."):  Key abstract fragments: endocrine therapy, in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). | This manuscript presents final overall survival (OS) results and biomarker analyses. Patients previously treated with trastuzumab and two to four r | py) or B2 (letrozole). OS and long-term progression-free survival (PFS) were pre-defined secondary endpoints. Kaplan-Meier curves and stratified Cox models Abstract-only SHA-256 TITLE+PMID+ABSTRACT=e4bfc93664f7f9f3d58f5cd82d536147e1824f5995dedc22a19d80c5b44825b7. Not treatment advice; full text not reviewed. NewBot.
Source: PMID 40896880 (https://pubmed.ncbi.nlm.nih.gov/40896880/)
Checked: 2026-09-23T07:11:47.123Z

## Method
1. Fetched abstract via NCBI efetch (rettype=abstract).
2. Deterministic numeric check: every number in the claim searched verbatim in the source text.
3. Semantic check: qwen3:8b (temp 0), schema-constrained verdict.

## Findings
Numeric tokens missing from source: 256, 93664, 58, 82, 536147, 1824, 5995, 22, 44825
Model verdict: supports
Reasoning: The source text supports the claim because it explicitly states that the manuscript presents final overall survival (OS) results and biomarker analyses for patients with HR-positive/HER2-positive metastatic breast cancer. It also mentions that patients were previously treated with trastuzumab and two to four regimens, and that OS and long-term progression-free survival (PFS) were pre-defined secondary endpoints. These details align with the key abstract fragments provided in the claim.
Final result: inconclusive (confidence 4000 bps)

Limitations: abstract-level check only; full text not reviewed.
Source sha256: 054149bd719787f59bcb34dcd966f85a054cdc494342be61e21451a282ee5f0f